Results 251 to 260 of about 72,150 (302)

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.

open access: yesBlood
Pauli C   +27 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Cytarabine

Journal of Pediatric Oncology Nursing, 1990
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine.
D L, Betcher, N, Burnham
openaire   +3 more sources

Cytarabine (Cytosar)

Clinical Pharmacology & Therapeutics, 1970
Warning. Only physicians experienced in cancer chemotherapy should use Cytosar. For induction therapy patients should be hospitalized in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.
openaire   +2 more sources

[Cytarabine].

Gan to kagaku ryoho. Cancer & chemotherapy, 1987
Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. Combination therapy of MFC (mitomycin C, 5-FU, ara-C) has been used for GI tract cancer with a synergistic effect on L-1210 mouse leukemia. In the results of research on the administration, a high dose ara-C is an effective agent in the refractory ...
openaire   +1 more source

Home - About - Disclaimer - Privacy